Gastroenterology — MCQs

Gastroenterology Indian Medical PG Practice Questions and MCQs

Question 361: A patient with compensated liver cirrhosis presented with a history of variceal bleed. What is the preferred mode of treatment in this patient?

A. Propranolol
B. Liver transplantation
C. TIPS
D. Endoscopic sclerotherapy (Correct Answer)

Explanation: The management of variceal bleeding is categorized into primary prophylaxis, management of acute episodes, and secondary prophylaxis. In this scenario, the patient has a history of variceal bleed, necessitating **secondary prophylaxis** to prevent recurrence [1]. **Why Endoscopic Sclerotherapy (EST) is the correct choice:** While Endoscopic Variceal Ligation (EVL) is currently considered the gold standard for secondary prophylaxis due to fewer complications, **Endoscopic Sclerotherapy (EST)** remains a primary therapeutic modality in many clinical guidelines and exam patterns for obliterating varices [1]. It involves injecting a sclerosant (e.g., ethanolamine oleate) into or around the vein, causing thrombosis and fibrosis. In the context of this specific question, it is the preferred interventional mode listed for preventing re-bleeding. **Why other options are incorrect:** * **Propranolol:** This is a non-selective beta-blocker used for **primary prophylaxis** (preventing the first bleed) or as an adjunct to endoscopic therapy for secondary prophylaxis. It is rarely used as a standalone "preferred mode" once a bleed has already occurred. * **Liver Transplantation:** This is the definitive treatment for end-stage liver disease (decompensated cirrhosis), not the immediate preferred management for isolated variceal bleeding in a **compensated** patient. * **TIPS (Transjugular Intrahepatic Portosystemic Shunt):** This is generally reserved for **refractory cases** where endoscopic and pharmacological treatments fail [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice for acute variceal bleed:** Terlipressin (Somatostatin/Octreotide are alternatives) [1]. * **Gold standard for secondary prophylaxis:** Combination of EVL + Beta-blockers. * **Most common cause of portal hypertension in India:** Non-cirrhotic portal fibrosis (NCPF), though cirrhosis is the leading cause globally. * **Child-Pugh Score:** Used to assess the prognosis of chronic liver disease and the risk of variceal bleeding.

Question 362: Which of the following statements about pseudomembranous colitis is false?

A. It commonly occurs after antibiotic use.
B. It is primarily caused by Clostridium difficile.
C. Oral vancomycin is a standard treatment.
D. None of the above statements are false. (Correct Answer)

Explanation: Pseudomembranous colitis is an inflammatory condition of the colon characterized by the presence of elevated yellow-white plaques (pseudomembranes) on the mucosal surface. 1. **Why Option D is correct:** All the provided statements (A, B, and C) are medically accurate descriptions of the disease's pathogenesis and management. Therefore, no statement is false. 2. **Analysis of Options:** * **Option A (True):** Antibiotic use is the primary risk factor. Broad-spectrum antibiotics (classically Clindamycin, Fluoroquinolones, and Cephalosporins) disrupt the normal colonic flora, allowing for the overgrowth of pathogenic bacteria [1]. * **Option B (True):** The causative agent is *Clostridioides difficile* (formerly *Clostridium*), a Gram-positive, spore-forming anaerobe [1]. It produces Toxin A (enterotoxin) and Toxin B (cytotoxin), which lead to mucosal inflammation and necrosis [1]. * **Option C (True):** Oral Vancomycin is a first-line treatment because it remains in the gut lumen and is not absorbed systemically, directly targeting the bacteria. Oral Fidaxomicin is another preferred first-line agent. **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Stool Cytotoxicity Assay (though rarely used now due to time). * **Most Sensitive Test:** GDH (Glutamate Dehydrogenase) screening. * **Most Specific/Practical Test:** Nucleic Acid Amplification Test (NAAT) for toxin genes. * **Endoscopy:** Shows characteristic "volcano lesions" or yellowish plaques. * **Treatment for Fulminant cases:** High-dose oral Vancomycin + IV Metronidazole. * **Recurrence:** Fecal Microbiota Transplant (FMT) is highly effective for multiple recurrences.

Question 363: In patients who have undergone appendicectomy, which of the following conditions is less likely to develop?

A. Ulcerative colitis (Correct Answer)
B. Crohn's disease
C. Both
D. None

Explanation: This question addresses a classic epidemiological observation in gastroenterology regarding the relationship between the appendix and Inflammatory Bowel Disease (IBD). [1] ### **Explanation** The correct answer is **Ulcerative Colitis (UC)**. Multiple large-scale epidemiological studies have demonstrated that **appendicectomy** (specifically when performed for true appendicitis or mesenteric adenitis at a young age) exerts a **protective effect** against the subsequent development of Ulcerative Colitis. [1] The underlying medical concept involves the appendix's role as a priming site for the mucosal immune system. It is hypothesized that the appendix contains a high concentration of T-cells and lymphoid tissue; its removal may alter the immune response or the gut microbiome in a way that prevents the specific inflammatory cascade required to trigger UC. ### **Analysis of Options** * **A. Ulcerative Colitis (Correct):** Appendicectomy is associated with a significantly lower risk of developing UC. Furthermore, if a patient does develop UC after an appendicectomy, the clinical course is often milder. * **B. Crohn’s Disease (Incorrect):** Unlike UC, appendicectomy does **not** protect against Crohn’s disease. [1] In fact, some studies suggest a slightly *increased* risk of being diagnosed with Crohn’s disease in the years immediately following an appendicectomy, though this may be due to diagnostic overlap (Crohn's presenting as pseudo-appendicitis). * **C & D (Incorrect):** Based on the divergent relationship between the two diseases and the appendix. ### **NEET-PG High-Yield Pearls** * **Smoking Paradox:** Smoking is **protective** in Ulcerative Colitis but is a major **risk factor** (increases severity/relapse) in Crohn’s Disease. * **Appendicectomy Paradox:** Appendicectomy is **protective** in Ulcerative Colitis but may be a **risk factor** or neutral in Crohn’s Disease. [1] * **Primary Sclerosing Cholangitis (PSC):** Strongly associated with UC (approx. 75% of PSC patients have UC). * **ASCA vs. p-ANCA:** Crohn’s is typically **ASCA positive**, while UC is typically **p-ANCA positive.**

Question 364: Which of the following findings is NOT typically seen in exudative ascites?

A. Protein > 2.5 gm/dl
B. Specific gravity > 1.016
C. Serum-Ascites Albumin Gradient (SAAG) > 1.1 gm/dl (Correct Answer)
D. None of the above

Explanation: The classification of ascites has shifted from the traditional transudate/exudate model to the more physiologically accurate **Serum-Ascites Albumin Gradient (SAAG)**. ### **Explanation of the Correct Answer** **Option C (SAAG > 1.1 g/dl)** is the correct answer because it is characteristic of **transudative (High-Gradient)** ascites, not exudative [1]. * **The Concept:** SAAG is calculated as *(Serum Albumin - Ascitic Fluid Albumin)*. A high gradient (> 1.1 g/dl) indicates that **portal hypertension** is the underlying cause [1]. The increased hydrostatic pressure pushes fluid out of the vessels while keeping albumin inside, creating a wide gap. * **Exudative ascites** (Low-Gradient, SAAG < 1.1 g/dl) occurs when there is increased capillary permeability or peritoneal inflammation (e.g., malignancy, tuberculosis), allowing albumin to leak into the peritoneal space, thus narrowing the gradient [1]. ### **Analysis of Incorrect Options** * **Option A (Protein > 2.5 gm/dl):** This is a classic criterion for exudative ascites [1]. In inflammatory or malignant conditions, the "leaky" membranes allow large protein molecules to enter the ascitic fluid. * **Option B (Specific gravity > 1.016):** High solute content (mainly proteins) increases the density of the fluid. A specific gravity greater than 1.016 is traditionally associated with exudates. ### **High-Yield Clinical Pearls for NEET-PG** 1. **High SAAG (> 1.1):** Cirrhosis (most common), Congestive Heart Failure, Budd-Chiari Syndrome, Portal vein thrombosis [1]. 2. **Low SAAG (< 1.1):** Peritoneal Carcinomatosis, Tuberculosis, Nephrotic Syndrome, Pancreatitis [1]. 3. **The "Cardiac Exception":** In Heart Failure, the SAAG is high (> 1.1), but the total protein is also high (> 2.5 g/dl) due to high hepatic sinusoidal pressure [1]. 4. **SAAG Accuracy:** It is 97% accurate in identifying portal hypertension, making it superior to the protein-based transudate/exudate classification [1].

Question 365: What is the cause of pruritus in primary biliary cirrhosis?

A. Toll-like receptor 4 (TLR4)
B. Glucagon-like peptide 1 (GLP-1)
C. Transient receptor potential vanilloid 1 (TRPV1) (Correct Answer)
D. Gastrin-releasing peptide (GRP)

Explanation: Pruritus is a common and distressing symptom of **Primary Biliary Cholangitis (PBC)**, formerly known as Primary Biliary Cirrhosis [1]. The pathophysiology involves the accumulation of cholestatic pruritogens (such as bile acids and lysophosphatidic acid) that activate specific neural pathways [2]. **Why TRPV1 is correct:** Recent research has identified **Transient Receptor Potential Vanilloid 1 (TRPV1)**, a non-selective cation channel found on sensory neurons, as a key mediator in cholestatic itch [2]. Pruritogens like **Lysophosphatidic Acid (LPA)**, formed by the enzyme autotaxin, activate these TRPV1 channels on peripheral nerve endings, leading to the transmission of the itch sensation to the central nervous system. **Analysis of Incorrect Options:** * **A. TLR4:** This is a pattern recognition receptor involved in innate immunity and the inflammatory response to LPS (endotoxin), not the primary mediator of pruritus. * **B. GLP-1:** This is an incretin hormone involved in glucose homeostasis and insulin secretion. * **D. GRP:** While Gastrin-releasing peptide is a known neurotransmitter in the spinal cord's "itch circuit," the specific peripheral trigger mechanism highlighted in recent PBC studies emphasizes the role of the TRPV1 channel. **High-Yield Clinical Pearls for NEET-PG:** * **First-line treatment for PBC pruritus:** Cholestyramine (bile acid sequestrant). * **Second-line/Alternative treatments:** Rifampicin (induces P450 to metabolize pruritogens), Naltrexone (opioid antagonist), and Sertraline (SSRI). * **Diagnostic Marker:** Anti-Mitochondrial Antibody (AMA) is positive in >95% of cases [3]. * **Key Enzyme:** **Autotaxin** levels correlate with the severity of cholestatic itch.

Question 366: What is the most common feature seen in patients with non-cirrhotic portal fibrosis?

A. Gastric varices
B. Esophageal varices (Correct Answer)
C. Ascites
D. Portal gastropathy

Explanation: **Non-Cirrhotic Portal Fibrosis (NCPF)**, also known as Idiopathic Portal Hypertension (IPH), is a clinical syndrome characterized by portal hypertension in the absence of cirrhosis, extrahepatic portal vein obstruction (EHPVO), or Budd-Chiari syndrome. It is primarily seen in the Indian subcontinent. **Why Esophageal Varices is the correct answer:** The hallmark of NCPF is **obliterative venopathy** of the small portal vein branches, leading to significant portal hypertension [3]. Because the liver function remains preserved (synthetic function is normal), the primary clinical manifestation is related to the high pressure in the portal system. **Esophageal varices** are the most common clinical feature, often presenting as massive, recurrent upper gastrointestinal bleeding [1]. Despite the severity of the bleed, these patients tolerate it much better than cirrhotic patients due to their healthy liver [4]. **Analysis of Incorrect Options:** * **Gastric Varices:** While they can occur in NCPF, they are less common than esophageal varices. Isolated gastric varices are more characteristic of splenic vein thrombosis (left-sided portal hypertension). * **Ascites:** This is typically **absent** or transient in NCPF [2]. Since the liver's synthetic function (albumin production) is maintained and there is no sinusoidal architectural distortion, ascites only develops briefly following a major variceal bleed or infection. * **Portal Gastropathy:** This may be present on endoscopy, but it is a secondary finding and not as prevalent or clinically defining as esophageal varices. **NEET-PG High-Yield Pearls:** * **Classic Triad of NCPF:** Massive Splenomegaly + Portal Hypertension + Preserved Liver Function. * **Histology:** Shows "obliterative portal venopathy," portal fibrosis, and "subcapsular atrophy," but **no cirrhosis** (no regenerative nodules). * **Prognosis:** Much better than cirrhosis because the Child-Pugh score usually remains Class A. * **Key Differential:** EHPVO (In EHPVO, the portal vein is thrombosed/cavernous; in NCPF, the main portal vein is patent but the intrahepatic branches are diseased).

Question 367: What is the best diagnostic test for esophageal motility disorders?

A. Barium studies
B. Esophagoscopy
C. 24-hour pH monitoring
D. Manometry (Correct Answer)

Explanation: **Explanation:** **Esophageal Manometry** is the **gold standard** and best diagnostic test for evaluating esophageal motility disorders (e.g., Achalasia cardia, Diffuse Esophageal Spasm, Nutcracker esophagus) [1]. It directly measures the pressure, timing, and coordination of the Lower Esophageal Sphincter (LES) and the esophageal body during swallowing. High-resolution manometry (HRM) is the modern iteration, providing a "topographic map" (Chicago Classification) to precisely categorize these disorders [1]. **Analysis of Incorrect Options:** * **Barium studies:** While often the initial screening test (showing the "bird’s beak" appearance in Achalasia or "corkscrew" esophagus in DES), it is a structural/radiological study and cannot definitively quantify pressure or motor function [1]. * **Esophagoscopy:** Primarily used to rule out mechanical obstructions or "pseudoachalasia" (malignancy at the GE junction) [1]. It cannot diagnose motility issues as the esophagus often appears normal or merely dilated. * **24-hour pH monitoring:** This is the gold standard for diagnosing **Gastroesophageal Reflux Disease (GERD)**, not motility disorders. It measures acid exposure time but does not assess peristalsis. **High-Yield Clinical Pearls for NEET-PG:** * **Achalasia Cardia:** Characterized on manometry by **incomplete LES relaxation** (Integrated Relaxation Pressure >15 mmHg) and **aperistalsis** in the distal esophagus [1]. * **Nutcracker Esophagus:** Characterized by high-amplitude peristaltic contractions (>180 mmHg) [1]. * **Initial vs. Best:** For dysphagia, the initial test is often Barium Swallow or Endoscopy, but the **most definitive/best** test for motility is always Manometry [1].

Question 368: All of the following are true of duodenal ulcer pain except:

A. Relieved by food
B. Occurs 2-3 hours after a meal
C. Periodic pain
D. Relieved by alcohol (Correct Answer)

Explanation: The correct answer is **D (Relieved by alcohol)**. Alcohol is a known gastric mucosal irritant that stimulates acid secretion [3] and delays mucosal healing; therefore, it typically **exacerbates** rather than relieves the pain of a duodenal ulcer (DU) [2]. **Analysis of Options:** * **A & B (Relieved by food / Occurs 2-3 hours after meals):** These are classic features of DU. In DU, pain occurs when the stomach is empty (the "hunger pain" cycle). Food or antacids buffer the acid, providing temporary relief. Pain typically returns 2–3 hours post-prandially when the acid load enters the duodenum [1]. * **C (Periodic pain):** DU pain is characteristically episodic or "periodic." Patients often experience symptomatic periods lasting several weeks followed by symptom-free intervals of weeks or months. **Clinical Pearls for NEET-PG:** 1. **Night Pain:** DU is the most common cause of nocturnal pain (occurring between 11 PM and 2 AM) because circadian acid secretion is highest at night. 2. **Food Relationship:** * **Duodenal Ulcer:** Food **relieves** pain (Weight gain may occur). * **Gastric Ulcer:** Food **aggravates** pain (Weight loss is common). 3. **Etiology:** *H. pylori* is the most common cause of DU (up to 90% of cases) [1]. 4. **Complications:** The most common complication of DU is **bleeding** (posterior wall), while the most common cause of **perforation** is an anterior wall ulcer [2].

Question 369: All are features of bile acid diarrhea, EXCEPT:

A. Extensive ileal involvement is seen
B. Hepatic synthesis compensates fecal loss
C. Reduced bile acid pool (Correct Answer)
D. Good response to cholestyramine

Explanation: This question tests your understanding of the **enterohepatic circulation** [2] and the pathophysiology of **Bile Acid Malabsorption (BAM)**, specifically the difference between Type I (limited) and Type II (extensive) ileal disease. ### **Explanation of the Correct Option** **C. Reduced bile acid pool:** This is the correct "Except" choice because, in cases of **limited ileal disease** (usually <100 cm of terminal ileum involvement), the liver is capable of increasing the synthesis of bile acids to compensate for fecal losses. This maintains a **normal bile acid pool**, ensuring that micelle formation and fat absorption remain intact. Diarrhea occurs because the unabsorbed bile acids enter the colon and stimulate water/electrolyte secretion (choleretic diarrhea) [2], [3]. ### **Analysis of Incorrect Options** * **A. Extensive ileal involvement:** While bile acid diarrhea occurs in limited disease, it is also a feature of extensive disease (>100 cm). However, in extensive disease, the liver *cannot* compensate, leading to a reduced pool and steatorrhea [1]. * **B. Hepatic synthesis compensates fecal loss:** This is the hallmark of Type I BAM (limited ileal resection/Crohn’s). The liver upregulates synthesis up to 10-fold to maintain the pool. * **D. Good response to cholestyramine:** Since the diarrhea is caused by the presence of bile acids in the colon, bile acid sequestrants like **Cholestyramine** bind these acids, effectively relieving the symptoms. ### **Clinical Pearls for NEET-PG** * **The 100 cm Rule:** * **<100 cm ileal loss:** Bile acid diarrhea (watery); Normal bile acid pool; Responds to Cholestyramine. * **>100 cm ileal loss:** Fatty acid diarrhea (steatorrhea); Reduced bile acid pool [1]; Responds to a Low-fat diet (Cholestyramine may worsen it by further depleting the pool). * **Gold Standard Test:** The **75SeHCAT test** (Selenium-labeled homocholic acid taurine) is the most sensitive test for diagnosing BAM. * **Vitamin Deficiency:** Always monitor for **Vitamin B12 deficiency** in patients with ileal involvement, as the terminal ileum is the primary site for the B12-Intrinsic Factor complex absorption.

Question 370: What is the major risk factor, along with alcohol intake, for the development of alcoholic liver disease?

A. Chronic HCV infection (Correct Answer)
B. Chronic HBV infection
C. Non hepatotropic virus infection
D. Abdominal tuberculosis

Explanation: The development and progression of alcoholic liver disease (ALD) are influenced by several cofactors, with **Chronic Hepatitis C Virus (HCV) infection** being the most significant. **1. Why Chronic HCV is the correct answer:** There is a synergistic relationship between alcohol consumption and HCV [1]. Alcohol enhances HCV replication and increases oxidative stress within hepatocytes [1]. Clinical studies consistently show that patients with both chronic HCV and heavy alcohol intake develop cirrhosis at a younger age, have a higher frequency of decompensation, and face a significantly increased risk of developing **Hepatocellular Carcinoma (HCC)** compared to those with either risk factor alone. **2. Why other options are incorrect:** * **Chronic HBV infection:** While HBV is a major cause of cirrhosis and HCC, its synergistic link with alcohol is less pronounced and less frequently documented in epidemiological studies compared to the alcohol-HCV interaction. * **Non-hepatotropic virus infection:** Viruses like CMV or EBV may cause transient hepatitis but do not lead to chronic liver disease or synergize with alcohol to promote cirrhosis. * **Abdominal tuberculosis:** This is an infectious granulomatous disease primarily affecting the peritoneum and bowel [2]. It does not directly accelerate the pathophysiological mechanisms of alcoholic steatohepatitis or fibrosis. **High-Yield Clinical Pearls for NEET-PG:** * **Gender:** Women are more susceptible to ALD than men at lower levels of alcohol intake due to lower levels of gastric alcohol dehydrogenase [1]. * **Obesity:** Non-alcoholic fatty liver disease (NAFLD) and alcohol have a "double hit" effect on liver fibrosis. * **Genetic Factor:** Polymorphisms in the **PNPLA3 gene** are strongly associated with an increased risk of alcoholic cirrhosis. * **Threshold:** The risk of cirrhosis increases significantly with the consumption of >30g of ethanol per day [1].

Practice by Chapter

Esophageal Disorders

Practice Questions

Peptic Ulcer Disease

Practice Questions

Inflammatory Bowel Disease

Practice Questions

Irritable Bowel Syndrome

Practice Questions

Malabsorption Syndromes

Practice Questions

Pancreatitis (Acute and Chronic)

Practice Questions

Gastrointestinal Bleeding

Practice Questions

Liver Diseases and Cirrhosis

Practice Questions

Viral Hepatitis

Practice Questions

Biliary Tract Disorders

Practice Questions

Gastrointestinal Motility Disorders

Practice Questions

Gastrointestinal Malignancies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free